Nucleoside transport in normal and neoplastic cells

https://doi.org/10.1016/0065-2571(93)90021-5Get rights and content

Abstract

The permeation of nucleosides across the plasma membrane of mammalian cells is complex and mediated by at least five distinct transporters that differ in their sensitivity to inhibitors and in their specificity for nucleosides. The basic properties and permeant specificity of these transporters are summarized in Table 3. It appears that there may be differences in the distribution of these transporters in tumors and normal tissues that might be exploited for chemotherapeutic purposes. The human tumor cell lines examined express predominantly the NBMPR-sensitive equilibrative transporter es which can be blocked by low concentrations of NBMPR and dipyridamole. It is reasonable to expect that tumors with transport properties similar to the CCRF-CEM and Rh28 cell lines (Table 1) that have no detectable NBMPR-insensitive transport activity will be highly susceptible to the therapeutic approach of combining a transport inhibitor such as dipyridamole or NBMPR with an inhibitor of de novo pyrimidine biosynthesis. On the other hand, this approach to therapy is unlikely to succeed against tumors with transport phenotypes similar to the WI-L2 cell line that may permit the salvage nucleosides in the presence of these inhibitors. The majority of tumor cells examined, however, fall between these extremes, and it is not yet known what level of NBMPR-insensitive transport activity can be tolerated without seriously compromising this therapeutic approach. With respect to normal tissues, the mature absorptive cells of the intestine have predominantly Na+-dependent nucleoside transporters that are insensitive to NBMPR and dipyridamole. The proliferating crypt cells also appear to have Na+-dependent nucleoside transport, although they may also have an NBMPR-sensitive component of transport (Belt, unpublished data). Bone marrow granulocyte-macrophage progenitor cells also appear to have one or more concentrative nucleoside transporters. Thus these tissues, which are most vulnerable to the toxicity of antimetabolites, may be able to salvage nucleosides in the presence of inhibitors of equilibrative transport and be protected from the toxicity of de novo synthesis inhibitors. It is likely, however, that a successful application of this therapeutic approach will require the analysis of the nucleoside transport phenotype of individual tumors in order to identify those patients that may benefit from such therapy. Since the development of antibodies (66–68) and cDNA probes (69, 70) for the various nucleoside transporters is currently underway in several laboratories, it is likely that analysis of the nucleoside transport phenotype of tumors from biopsy material will be feasible in the future.

References (71)

  • P.G.W. Plagemann et al.

    Na+-Dependent and -independent transport of uridine and its phosphorylation in mouse spleen cells

    Biochim. Biophys. Acta

    (1989)
  • H.P. Baer et al.

    Sodium-dependent and inhibitor-insensitive uptake of adenosine by mouse peritoneal exudate cells

    Biochim. Biophys. Acta

    (1990)
  • P.G.W. Plagemann et al.

    Characterization of Na+-dependent, active nucleoside transport in rat and mouse peritoneal macrophages, a mouse macrophage cell line and normal rat kidney cells

    Biochim. Biophys. Acta

    (1990)
  • R. Spector

    Nucleoside transport in choroid plexus: mechanism and specificity

    Arch. Biochem. Biophys.

    (1982)
  • X. Wu et al.

    Sodium-dependent nucleoside transport in choroid plexus from rabbit. Evidence for a single transporter for purine and pyrimidine nucleosides

    J. Biol. Chem.

    (1992)
  • C.R. Crawford et al.

    Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters

    J. Biol. Chem.

    (1990)
  • P.G.W. Plagemann et al.

    Na+-dependent, active and Na+-independent, facilitated transport of formycin B in mouse spleen lymphocytes

    Biochim. Biophys. Acta

    (1990)
  • C.R. Crawford et al.

    Sodium-dependent, concentrative nucleoside transport in Walker 256 rat carcinosarcoma cells

    Biochem. Biophys. Res. Commun.

    (1991)
  • C.R. Crawford et al.

    Isolation and characterization of an L1210 cell line retaining the sodium-dependent carrier cif as its sole nucleoside transport activity

    J. Biol. Chem.

    (1990)
  • A.M. Pajor et al.

    Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family

    J. Biol. Chem.

    (1992)
  • T.C. Chan et al.

    Mechanism of synergy between N-phosphonacetyl-l-aspartate and dipyridamole in a human ovarian carcinoma cell line

    Cancer Res.

    (1985)
  • T.C. Chan et al.

    Modulation of the activity of PALA by dipyridamole

    Cancer Treat. Rep.

    (1985)
  • C.T. Warnick et al.

    Interference with nucleoside transport in mouse lymphoma cells proliferating in culture

    Cancer Res.

    (1972)
  • J.A. Nelson et al.

    Potentiation of methotrexate toxicity by dipyridamole

    Cancer Res.

    (1984)
  • F.R. Ungemach et al.

    Uptake of thymidine into isolated rat hepatocytes. Evidence for two transport systems

    Hoppe-Seyler's Z. Physiol. Chem.

    (1978)
  • S. Cabral et al.

    Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells

  • F.M. Muggia et al.

    Characterization of conditions in which dipyridamole enhances methotrexate toxicity in L1210 cells

    Anticancer Res.

    (1987)
  • M. Kubota et al.

    Prevention of 1-β-d-arabinofuranosylcytosine toxicity by 4-nitrobenzyl-6-thioinosine or dipyridamole in human leukemia cell lines

    Anticancer Res.

    (1988)
  • Y. Zhen et al.

    Effects of acivicin and dipyridamole on hepatoma 3924A cells

    Cancer Res.

    (1983)
  • G. Weber

    Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture

    Cancer Res.

    (1983)
  • P.H. Fischer et al.

    Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole

    Cancer Res.

    (1984)
  • Y.S. Zhen et al.

    Effects of acivicin and dipyridamole on hepatoma 3924A cells

    Cancer Res.

    (1983)
  • Y.S. Zhen et al.

    Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells

    Oncology Res.

    (1992)
  • J.K. Willson et al.

    Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage

    Cancer Res.

    (1988)
  • J.K. Willson et al.

    Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans

    Cancer Res.

    (1989)
  • Cited by (168)

    • Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers

      2018, PET Clinics
      Citation Excerpt :

      FLT enters tissue by Na+-dependent active transporters dominated by human equilibrative nucleoside transporter 1. The level of this transporter increases as proliferating cells enter the cell cycle; accordingly, the expression is upregulated in the setting of cancer45 and this might influence radiotracer uptake and signal in the in vivo setting.46 [ 18F]FLT is phosphorylated in the cells by thymidine kinase-1 resulting in intracellular trapping and accumulation of this tracer; but unlike thymidine, FLT is not incorporated into the DNA structure.

    • Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer

      2012, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Curtin NJ and colleagues [25] showed that pyrimido[5,4-d]pyrimidines act as anti-metabolites, although they were designed as anti-cancer agents, and they still represent a major class with wide therapeutic applications today. Salvage of extracellular purine or pyrimidine nucleosides or bases constitutes an intrinsic resistance mechanism to anti-metabolite inhibitors of de novo purine or pyrimidine biosynthesis [26,27]. The pyrimido–pyrimidine cardiovascular agent DP inhibits equilibrative nucleoside transporters [28–30].

    View all citing articles on Scopus
    View full text